Filing summary
Entity and period: The supplied filing is KBL Merger Corp. IV’s Form 10-K for the fiscal year ended December 31, 2017, not a filing identified as FORUM MARKETS Inc. The company was a Nasdaq-listed blank-check company seeking a business combination, primarily in healthcare and wellness; it had not completed one by year-end.
Financial results and position
| Metric | 2017 | Q4 2017 |
|---|---|---|
| Operating revenue | None | None |
| Operating costs / loss from operations | $343,884 | $121,339 |
| Interest income | $663,017 | $273,383 |
| Income tax provision | $195,369 | $88,429 |
| Net income | $123,764 | $63,615 |
| Basic / diluted earnings per share | $0.04 / $0.01 | $0.02 / $0.00 |
- Cash flow: FY operating cash used was $497,357; investing cash used was $115.925 million, primarily reflecting trust funding; financing cash provided was $116.784 million.
- Year-end assets and liquidity: Total assets were $117.058 million, including $116.588 million in cash and marketable securities in trust and $428,393 cash outside the trust. The outside-trust cash was available for search and corporate costs.
- Liabilities and equity: Total liabilities were $4.233 million, including $4.025 million of deferred underwriting fees payable upon a business combination. Stockholders’ equity was $5.000 million; $107.825 million of shares were classified as subject to possible redemption. No long-term debt was reported.
- Margins: Operating and profit margins are not meaningful because the company had no operating revenue and income was generated from trust-account interest.
- Trust funds: Trust assets were invested principally in short-term U.S. Treasury bills. The filing reports approximately $112.563 million available for a business combination after deferred underwriting fees, assuming no redemptions.
Changes and comparison
The 2017 results reflect the June 2017 IPO and trust-account investment; 2016 covered only the period from the company’s September 2016 inception and showed a $3,105 net loss with no operating revenue. The 2017 net income therefore arose from trust interest, not business operations. Within 2017, Q4 net income was $63,615, compared with $86,116 in Q3, as interest income fell from $333,905 to $273,383 and operating costs declined from $140,849 to $121,339. The filing provides no comparable full-year operating-company results.
Outlook, risks and unusual items
- The company intended to pursue a healthcare or wellness acquisition, while retaining flexibility to consider other industries. General target guidelines included EBITDA above $15 million and valuation of $300 million to $700 million; these were not binding criteria.
- The company had to complete a business combination by December 7, 2018, or potentially March 7, 2019 if it had entered into a qualifying agreement by the earlier deadline. Failure to do so would trigger liquidation and redemption of public shares, subject to creditor claims and applicable law; rights and warrants would expire worthless.
- The independent auditor’s report included a going-concern explanatory paragraph, citing substantial doubt arising from the mandatory liquidation deadline. Management stated it believed available working capital was sufficient through the scheduled deadline, but sponsor or management loans were optional, not committed.
- Management reported no off-balance-sheet arrangements and no long-term debt. The company had no operating revenues, and expected continuing costs for public-company compliance and acquisition searches.
- Key risks include failure to find or close a suitable transaction before the deadline, limited cash outside the trust, redemption levels that could undermine transaction funding, competition for targets, dilution or debt financing, conflicts of interest, and possible creditor claims against trust assets. The sponsor’s trust-protection indemnity may be difficult to collect; the filing says its financial capacity was not independently verified.
- At December 31, 2017, disclosure controls were assessed as effective. The filing reported no material changes in internal control over financial reporting during the most recent quarter, but did not include management’s internal-control assessment or auditor attestation due to the applicable newly public company transition period.
Investor verification points
- Confirm the issuer identity: this source is KBL Merger Corp. IV, despite the request metadata naming FORUM MARKETS Inc.
- Verify the trust balance, deferred underwriting fee, redemption terms and applicable combination deadline, including any later amendments or subsequent business-combination filings.
- Assess whether the company completed a transaction or liquidated after the 10-K reporting date; this filing alone does not establish the later outcome.
- Review the going-concern warning, the limited outside-trust cash, sponsor indemnity capacity and potential creditor claims that could reduce public-stockholder recoveries.
- Evaluate dilution and conflicts arising from founder shares, private-placement securities, warrants and rights, sponsor voting commitments, and possible related-party transactions or loans.